Hepion Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell on February 10, 2023

Rhea-AI Summary

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced that CEO Robert Foster will ring the Nasdaq Closing Bell on February 10, 2023. The event highlights the company’s focus on AI-driven therapeutic development for conditions like NASH and hepatocellular carcinoma. Rencofilstat, its lead drug candidate, has shown efficacy in reducing liver fibrosis and tumor burden and is currently in Phase 2 clinical development for NASH. The FDA has granted it both Fast Track and Orphan Drug designations. Hepion also introduced its AI-POWR™ platform, aimed at improving patient outcomes in clinical trials and exploring new therapeutic indications.

Positive

• Rencofilstat shows promise in reducing liver fibrosis and tumor burden.
• FDA granted Fast Track and Orphan Drug designations for rencofilstat.
• AI-POWR™ platform aims to enhance patient selection and development timelines.

Negative

• None.

EDISON, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that its CEO, Robert Foster, PharmD, PhD, will lead it in ringing the Nasdaq Closing Bell on Friday, February 10, 2023.

The Closing Bell ceremony will be broadcast live starting at 3:45 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York City. To view the broadcast, please visit www.nasdaq.com/marketsite/bell-ringing-ceremony or www.Facebook.com/Nasdaq.

About Hepion Pharmaceuticals

The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models and is currently in Phase 2 clinical development for the treatment of NASH. In November 2021, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for rencofilstat for the treatment of NASH. That was followed in June 2022 by the FDA’s granting of Orphan Drug designation to rencofilstat for the treatment of HCC.

Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to rencofilstat, potentially shortening development timelines and increasing the observable differences between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for rencofilstat to expand the company's footprint in the cyclophilin inhibition therapeutic space.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com

FAQ

What is the significance of Hepion ringing the Nasdaq Closing Bell?

It highlights Hepion Pharmaceuticals' achievements and raises awareness of its initiatives in biopharmaceutical development.

What is rencofilstat used for?

Rencofilstat is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

What designations has rencofilstat received from the FDA?

Rencofilstat has received Fast Track and Orphan Drug designations from the FDA.

What is the AI-POWR™ platform?

AI-POWR™ is Hepion's proprietary platform designed to leverage AI for patient selection and improve clinical trial outcomes.